Various studies have been conducted to evaluate different treatment options and prognostic factors for stage II and III colon cancer, including perioperative chemotherapy, gene expression assays, microsatellite instability, timing of adjuvant chemotherapy, hyperthermic intraperitoneal chemotherapy, and the impact of different chemotherapy regimens on survival.